· 1d
Johnson & Johnson Tops Q4 EPS Forecasts
· 1d
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
· 1d
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
· 9h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
· 1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
US approves first nasal spray for major depressive disorder, PTSD conditions
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),
Some results have been hidden because they may be inaccessible to you
Show inaccessible results